As pristanic acid could serve as an efficient agonist of PPARα, it is possible that an increased level of pristanic acid could result in decreased activity of PPARα [38], which in turn causes dysregulation of lipid metabolism and body weight [42, 49], thereby contributing to obesity pathogenesis. The gene discussed is PPARA; the disease is obesity due to melanocortin 4 receptor deficiency.